Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

927 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
van Zuylen L, Bridgewater J, Sparreboom A, Eskens FA, de Bruijn P, Sklenar I, Planting AS, Choi L, Bootle D, Mueller C, Ledermann JA, Verweij J. van Zuylen L, et al. Among authors: verweij j. Clin Cancer Res. 2004 Mar 15;10(6):1949-55. doi: 10.1158/1078-0432.ccr-02-0995. Clin Cancer Res. 2004. PMID: 15041711 Free article. Clinical Trial.
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Soepenberg O, Dumez H, Verweij J, Semiond D, deJonge MJ, Eskens FA, ter Steeg J, Selleslach J, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Soepenberg O, et al. Among authors: verweij j. J Clin Oncol. 2005 Feb 1;23(4):889-98. doi: 10.1200/JCO.2005.01.008. J Clin Oncol. 2005. PMID: 15681535 Clinical Trial.
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O, Dumez H, Verweij J, de Jong FA, de Jonge MJ, Thomas J, Eskens FA, van Schaik RH, Selleslach J, Ter Steeg J, Lefebvre P, Assadourian S, Sanderink GJ, Sparreboom A, van Oosterom AT. Soepenberg O, et al. Among authors: verweij j. Clin Cancer Res. 2005 Feb 15;11(4):1504-11. doi: 10.1158/1078-0432.CCR-04-1758. Clin Cancer Res. 2005. PMID: 15746053 Free article. Clinical Trial.
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Hoekstra R, Dumez H, Eskens FA, van der Gaast A, Planting AS, de Heus G, Sizer KC, Ravera C, Vaidyanathan S, Bucana C, Fidler IJ, van Oosterom AT, Verweij J. Hoekstra R, et al. Among authors: verweij j. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6908-15. doi: 10.1158/1078-0432.CCR-05-0720. Clin Cancer Res. 2005. PMID: 16203782 Clinical Trial.
927 results